# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportuni...
JMP Securities analyst Reni Benjamin initiates coverage on BeiGene (NASDAQ:BGNE) with a Market Outperform rating and announc...
Key Takeaways: Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allow...
The FDA's Fast track designation is aimed to facilitate the development and expedite the review of drugs to treat serious c...